Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Favipiravir and Zanamivir Cleared Infection with Influenza B in a Severely Immunocompromised Child.

Literature DB >> 32124919

Favipiravir and Zanamivir Cleared Infection with Influenza B in a Severely Immunocompromised Child.

Casper K Lumby¹, Lei Zhao¹, Macarena Oporto², Tim Best², Helena Tutill³, Divya Shah³, Paul Veys², Rachel Williams³, Austen Worth², Christopher J R Illingworth^1,4, Judy Breuer^2,3.

Abstract

A combination of favipiravir and zanamivir successfully cleared influenza B infection in a child who had undergone bone marrow transplant for X-linked severe combined immunodeficiency, with no recovery of T lymphocytes. Deep sequencing of viral samples illuminated the within-host dynamics of infection, demonstrating the effectiveness of favipiravir in this case.

Entities: Chemical Disease Species

Keywords: favipiravir; genome sequencing; influenza; zanamivir

Year: 2020 PMID： 32124919 DOI： 10.1093/cid/ciaa023

Source DB: PubMed Journal: Clin Infect Dis ISSN： 1058-4838 Impact factor: 9.079

Keyword Cloud
Cited

12 in total

1. Evolution of viral variants in remdesivir-treated and untreated SARS-CoV-2-infected pediatrics patients.

Authors: Florencia A T Boshier; Juanita Pang; Justin Penner; Matthew Parker; Nele Alders; Alasdair Bamford; Louis Grandjean; Stephanie Grunewald; James Hatcher; Timothy Best; Caroline Dalton; Patricia Dyal Bynoe; Claire Frauenfelder; Jutta Köeglmeier; Phoebe Myerson; Sunando Roy; Rachel Williams; Thushan I de Silva; Richard A Goldstein; Judith Breuer
Journal: J Med Virol Date: 2021-09-04 Impact factor: 20.693

Review 2. Preparing for the 2020-2021 influenza season.

Authors: Annabelle de St Maurice; Rachel Martin-Blais; Natasha Halasa
Journal: Pediatr Transplant Date: 2021-04-27

3. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity.

Authors: Suzanne J F Kaptein; Sofie Jacobs; Lana Langendries; Laura Seldeslachts; Sebastiaan Ter Horst; Laurens Liesenborghs; Bart Hens; Valentijn Vergote; Elisabeth Heylen; Karine Barthelemy; Elke Maas; Carolien De Keyzer; Lindsey Bervoets; Jasper Rymenants; Tina Van Buyten; Xin Zhang; Rana Abdelnabi; Juanita Pang; Rachel Williams; Hendrik Jan Thibaut; Kai Dallmeier; Robbert Boudewijns; Jens Wouters; Patrick Augustijns; Nick Verougstraete; Christopher Cawthorne; Judith Breuer; Caroline Solas; Birgit Weynand; Pieter Annaert; Isabel Spriet; Greetje Vande Velde; Johan Neyts; Joana Rocha-Pereira; Leen Delang
Journal: Proc Natl Acad Sci U S A Date: 2020-10-09 Impact factor: 11.205

Favipiravir and Zanamivir Cleared Infection with Influenza B in a Severely Immunocompromised Child.

1. Evolution of viral variants in remdesivir-treated and untreated SARS-CoV-2-infected pediatrics patients.

Review 2. Preparing for the 2020-2021 influenza season.

3. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity.

4. Favipiravir Inhibits Hepatitis A Virus Infection in Human Hepatocytes.

Review 5. Preclinical and clinical developments for combination treatment of influenza.

Review 6. Nanomaterial-based drug delivery systems as promising carriers for patients with COVID-19.

Review 7. Understanding the Impact of Resistance to Influenza Antivirals.

8. A large effective population size for established within-host influenza virus infection.

Review 9. Imposed mutational meltdown as an antiviral strategy.

Review 10. A global treatments for coronaviruses including COVID-19.